Oncology Impact Fund 2, L.P.
3 additional placement agents
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- +21%reported GAV
Reported gross assets rose from $826M to $1B between the Form ADV filings of 26 Jun 2024 and 28 Apr 2026.
The fund's assets as the adviser swears them, never its size or dry powder.
Amounts, each with its basis
- Vintage
- 2020basis: form d first sale
- Target
- unknownnot announced
- First close
- unknownnever inferred from a Form D
- Final close
- unknownonly from an announcement or an LP disclosure
- Announced size
- unknown
- Form D offering
- indefinitewhat may be sold, not what was raised; file 021-422030, sworn by the adviser or filed under this vehicle
- Form D sold
- $327Mas of the filing of Nov 22, 2021, 31 investors
- First sale
- Aug 4, 2020
- Reported GAV
- $1.0Bon the Form ADV filed Apr 28, 2026; the fund's assets, never its size or dry powder
- Owners (ADV)
- 33
- Reported on ADV
- Mar 30, 2023 to Apr 28, 2026
- Structure
- master
Fundraising evidence
What counts as raisingA Form D offering is permission to sell, not a fund in market; an amount sold is never a close; an evergreen offering amended every year is not a raise.Lifecycle
Mature
Lifecycle
The fund's own reporting through time
| Filed | Type | Gross asset value | Owners | Min. investment | Adviser-owned | Audit | |
|---|---|---|---|---|---|---|---|
| Mar 30, 2023 | Other Private Fund | $828M | 32 | $5.0M | 1% | yes | |
| Oct 30, 2023 | Other Private Fund | $828M | 32 | $5.0M | 1% | yes | |
| Mar 28, 2024 | Other Private Fund | $826M | 32 | $5.0M | 1% | yes | |
| Jun 6, 2024 | Other Private Fund | $826M | 32 | $5.0M | 1% | yes | |
| Jun 6, 2024 | Other Private Fund | $826M | 32 | $5.0M | 1% | yes | |
| Jun 26, 2024 | Other Private Fund | $826M | 32 | $5.0M | 1% | yes | |
| Apr 28, 2026 | Other Private Fund | $1.0B | 33 | $5.0M | 1% |
Principals and agents
- MPM Oncology Investments 2 LLC Promoter
- Ansbert Gadicke Executive Officer
- UBS Financial Services Inc. placement agent
Service providers
- AuditorKPMG · GRAND CAYMAN, Cayman IslandsForm ADV filed Apr 28, 2026 reports.adviserinfo.sec.gov
- AdministratorStandish Management · SAN FRANCISCO, California, United StatesForm ADV filed Apr 28, 2026 reports.adviserinfo.sec.gov
- CustodianPACIFIC WESTERN BANK · NEWTON, Massachusetts, United StatesForm ADV filed Apr 28, 2026 reports.adviserinfo.sec.gov
Limited partners and their reported performance
Whose numbers these areEach row is the LP’s own number: its cash flows and its valuation policy as of its reporting date, not the fund’s. Net IRR is printed only when the LP prints one. The vintage is the LP’s definition (CalPERS: year of its first cash flow; WSIB: year of its initial investment).Known LPs and allocators
What these amounts and dates areA commitment date prints only when the source printed one; otherwise the row carries the date of the report that listed it. A foundation’s 990-PF line is a holding at fair value on its return, never a commitment.Investments attributed to this vehicle
Timeline
- Jun 26, 2024Administrator changed: Standish Management replaced Apex Group, first reported on the Form ADV filed June 26, 2024 (previous filing June 6, 2024)Administrator changed Fact Form ADV
- Mar 30, 2023Oncology Impact Fund 2, L.P. first reported on Form ADV by MPM Asset Management LLC (Other Private Fund), GAV $828,188,146Fund first reported on Form ADV Fact Form ADV
- Mar 23, 2022Administrator changed: Apex Group replaced BROADSCOPE FUND ADMINISTRATORS, first reported on the Form ADV filed March 23, 2022 (previous filing July 13, 2021)Administrator changed Fact Form ADV
- Mar 23, 2022Custodian changed: BNY, Silicon Valley Bank replaced Apex Group, Carta, COWEN PRIME SERVICES LLC, first reported on the Form ADV filed March 23, 2022 (previous filing July 13, 2021)Custodian changed Fact Form ADV
- Nov 22, 2021Oncology Impact Fund 2, L.P. filed Form D: $326,820,000 sold (indefinite offering), Private Equity FundForm D filed Fact Form D
Evidence
Every observation on this vehicle
- Entity type: Other Nov 22, 2021 Fact Form D
- Form D fund type: Private Equity Fund Nov 22, 2021 Fact Form D
- Form D industry group: Pooled Investment Fund Nov 22, 2021 Fact Form D
- Amendment: false Nov 22, 2021 Fact Form D
- Revenue range (Form D): Decline to Disclose Nov 22, 2021 Fact Form D
- Incorporated: withinFiveYears Nov 22, 2021 Fact Form D
- Jurisdiction: CAYMAN ISLANDS Nov 22, 2021 Fact Form D
- Amount sold (Form D): $327M Nov 22, 2021 Fact Form D
- Exemptions: 06b, 3C, 3C.7 Nov 22, 2021 Fact Form D
- First sale: 2020-08-04 Nov 22, 2021 Fact Form D
- Indefinite offering: true Nov 22, 2021 Fact Form D
- Investors (Form D): 31 Nov 22, 2021 Fact Form D
- Minimum investment (Form D): 0 Nov 22, 2021 Fact Form D
- Securities offered: pooled Nov 22, 2021 Fact Form D
- Office address: Nov 22, 2021 Fact Form D
- Year of incorporation: 2020 Nov 22, 2021 Fact Form D
Relationships across DFX
on 2 other DFX graphs
Oncology Impact Fund 2, L.P. is the same institution as 2 records in RIA and Wealth and Private Equity.
DFX found 2 relationships across 2 datasets
Which record it is in each graph, what it is called there, and how the two were matched.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Checking your plan…
Record history
- Fund first reported on ADV2023-03-30source on record
- Form D filed2021-11-22source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.